Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp.

doi:10.21203/rs.3.rs-1799732/v1

Download PDF

Article

Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp.

https://doi.org/10.21203/rs.3.rs-1799732/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Predictors for the risk of severe COVID-19 are crucial for patient care and control of the disease. Other infectious diseases as potential comorbidities in SARS-CoV-2 infection are still poorly understood. Here we identify association between the course of COVID-19 and Lyme disease (borreliosis), caused by Borrelia burgdorferi transmitted to humans by ticks.

Exposure to Borrelia was identified by multi-antigenic (19 antigens) serological testing of patients: severe COVID-19 (hospitalized), asymptomatic to mild COVID-19 (home treated or not aware of being infected), and not infected with SARS-CoV-2. Increased levels of Borrelia-specific IgGs strongly correlated with COVID-19 severity and risk of hospitalization. This suggests that a history of tick bites and related infections may contribute to the risks in COVID-19. Though mechanisms of this link is not clear yet, screening for antibodies targeting Borrelia may help accurately assess the odds of hospitalization for SARS-CoV-2 infected patients, supporting efforts for efficient control of COVID-19.

Borreliosis, also known as Lyme disease, is a zoonosis caused by the bacterium Borrelia burgdorferi transmitted to humans by ticks. A characteristic symptom of infection is the skin rash called erythema migrans, which however occurs in only 60–80% of infected persons, with a delay of 3–30 days after the tick bite. Other typical symptoms are non-specific, including fever, mild headaches, muscular-articular pain, and fatigue. Thus, a considerable number of cases of Borrelia infection can be overlooked, while if left untreated, infection can spread to joints, the heart, and the nervous system^1–3. Subjective symptoms may persist or recur for at least six months after a patient was infected, even after antimicrobial treatment^3,4. So-called ‘chronic Lyme disease’, sometimes with severe manifestations, remains controversial, lacking clearly recognized or demonstrated significance for a patient’s health⁵.

The diagnostics of Borrelia infection is challenging, primarily due to the multitude of bacterial strains that may cause the infection. In Eurasia, Borrelia burgdorferi sensu lato includes various spirochete species: B. burgdorferi sensu stricto (s.s.), B. afzelii, B. garinii, B. bavariensis, B. japonica, B. lusitaniae, B. sinica, B. spielmanii, B. tanukii, B. turdi, B. valaisiana, B. yangtze, B. bissettii, and B. carolinensis. Within the area of this study (Central Europe), the predominant species as the causative agents of borreliosis are Borrelia afzelii and Borrelia garinii, less frequently Borrelia burgdorferi s.s.^6–8. B. spielmanii has also been found in an animal reservoir, postulated as an appropriate antigenic component in diagnostic tests in Europe⁹.

Serological testing of patients’ sera with antigens representing pathogenic species of Borrelia is the major approach in diagnostics¹⁰, even though seropositivity alone is not sufficient for a diagnosis of active borreliosis, since antibodies may persist for long after treatment of the disease and they can be detected even in individuals after a successful treatment ⁴. Proper interpretation of a patient’s clinical status is difficult due to different life strategies of B. burgdorferi; these are related to their antigenic variability, which is in turn linked to adaptation to different environmental conditions, their intracellular residence, and their hiding in immunologically privileged areas^11,12. Presence of antibodies targeting multiple antigens of Borrelia, however, indicates that an individual has been infected, without a clear indication of whether the infection has been eradicated or it is still active. Thus, serological testing remains the major tool available for epidemiological studies¹⁰.

The emergence of COVID-19, a new disease caused by the previously unknown SARS-CoV-2 virus, is linked to still very high uncertainty about factors that determine the clinical manifestation and course of this disease. The course of COVID-19 ranges from asymptomatic or mild to severe or fatal with fulminant development and dramatic symptoms. Some crucial conditions in COVID-19 have been revealed, including comorbidities such as diabetes, cardiovascular diseases, cancer, pulmonary disorders, and immunological disorders, but also obesity, advanced age, and others^13–15. Infectious diseases, however, have been much less recognized as comorbidities in SARS-CoV-2 infection and their potential effect on the risk of severe COVID-19 is poorly understood. Particularly, the possible association between Lyme disease and COVID-19 disease has not been established, in spite of indications that flu-like symptoms reported in both Lyme disease and COVID-19 can be very similar¹⁶. One available case report by Shutikova et al. (2021) describes a patient with disseminated Borrelia infection (starting in mid-2019), after an unsuccessful first round of antibiotic treatment (early 2020), who was infected with SARS-CoV-2 (mid-2020). Anti-COVID-19 treatment included umifenovir, hydroxychloroquine, azithromycin, and ceftriaxone, and it resulted in suppression of borreliosis, as manifested by the first decrease of anti-Borrelia IgG in diagnostics. However, that report was not dedicated to possible effects of borreliosis on the course of COVID-19¹⁷. Piotrowski and Rymaszewska (2022) pointed out a reduced number of cases of Lyme disease registered during the COVID-19 pandemic in Poland, and they concluded that it may result from limited outdoor activities in the lockdown, but possibly also from poor access of patients to the overburdened health care system¹⁸.

Further studies, for instance on the potential association of borreliosis with increased risk of SARS-CoV-2 infection or with severe COVID-19, have not been reported so far. In this study we analyzed a wide range of anti-Borrelia IgG and IgM antibodies (targeting 19 antigens derived from Borrelia spp.) in patients representing three different types of clinical history: severe COVID-19 (hospitalized), asymptomatic to mild COVID-19 (home treated or not aware of being infected), and not infected with SARS-CoV-2, to identify potential association between previous exposure to Borrelia spp. and the risk of SARS-CoV-2 infection or severe COVID-19.

A multi-antigen Microblot-Array for the diagnostics of Borrelia species was conducted in three groups of patients: with severe COVID-19 (hospitalized), with asymptomatic to mild COVID-19 (home treated or not aware of being infected), and those not infected with SARS-CoV-2. The groups were agreed for consistent demographic parameters (Supplementary Fig. S1 and S2). This testing revealed that all patients hospitalized due to COVID-19 disease were positive for Borrelia burgdorferi-specific IgG (31 out of 31). In patients with mild/asymptomatic COVID-19, 19 positive cases were found (out of 28), and in participants never infected with SARS-CoV-2 only 8 positive cases were found (out of 28) (as assessed according to the manufacturer’s instructions for array interpretation).

For 6 out of 19 Borrelia antigens tested, severe COVID-19 patients demonstrated significantly higher specific IgG serum levels than any other group of patients: VlsE B. garinii, p41 B. burgdorferi sensu stricto, OspB, OspA B. burgdorferi sensu stricto, OspC B. garinii, and OspC B. burgdorferi sensu stricto. For a further 10 Borrelia antigens, severe COVID-19 patients also demonstrated significantly higher specific IgG serum levels than participants not infected with SARS-CoV-2: VlsE B. afzelii, VlsE B. burgdorferi sensu stricto, p58, p41 B. afzelii, p39, OspA B. garinii, OspC B. afzelii, OspC B. spielmanii, Nap A and p17 (Fig. 1, all p-values are listed in Supplementary Table S1, numbers of patients testing positively for each antigen-specific IgG are listed in Supplementary Table S2). This observation suggests that previous exposure to Borrelia renders patients more prone to severe COVID-19 in case of SARS-CoV-2 infection.

Table 1

Antigens tested in this study; Ba – *B. afzelii*, Bg – *B. garinii*, Bs – *B. burgdorferi* sensu stricto, Bsp – *B. spielmanii*

(modified from manufacturer’s instructions: BioVendor Group, Brno Czech Republic, Microblot-Array Manual)
Antigen	Description
VlsE Ba	Expressed part of variable major protein-like sequence, significant for IgG antibody response, species-specific antigen
VlsE Bg
VlsE Bs
A4 p83	Main extracellular protein (product of p100 degradation)
p58	OppA-2 (oligopeptide permease 2) – membrane transporter, is considered a marker of disseminated stage of Lyme disease
p41 Ba	Internal flagellin, highly specific antigen of early antibody response
p41 Bs
p39	BmpA (glycosaminopeptide receptor) – marker of late IgG antibody response
OspB	Outer surface protein B, marker of late stage of infection, considered a marker of Lyme arthritis
OspA Ba	Outer surface protein A, highly specific marker of Borrelia infection in IgG class
OspA Bg
OspA Bs
OspC Ba	Outer surface protein C – main antigen of early antibody response, immunodominant marker of IgM antibody response
OspC Bg
OspC Bs
OspC Bsp
OspE	Outer surface protein E
NapA	Neutrophil activating protein A – strong immunogen, main marker of Lyme arthritis pathogenesis
p17	DbpA (decorin-binding protein A) – outer membrane protein
p44	Anaplasma phagocytophilum – main marker of human granulocytic anaplasmosis antibody response
OmpA	Outer membrane protein A of Anaplasma phagocytophilum; peptidoglycan-associated lipoprotein, significant virulence marker
Asp62	Surface protein – membrane transporter
TpN17	Highly specific membrane protein of Treponema pallidum
VCA-p18	Viral capsid antigen p18 – important marker of EBV infection

Severe COVID-19 patients also demonstrated significantly higher levels of IgGs specific to Anaplasma antigens (OmpA and Asp62) (Fig. 1), while Anaplasma is often co-transmitted with Borrelia by ticks. This further supports the suggestion that increased risks in COVID-19 are linked to a history of ticks bites and related infections.

Testing for Borrelia-specific IgM revealed that among patients hospitalized due to COVID-19 disease, 24 (out of 31) were positive for Borrelia burgdorferi-specific IgM, while in mild/asymptomatic patients and in participants never infected with SARS-CoV-2 only 13 (out of 28) and 15 (out of 28) positive cases were found, respectively. Significant differences between groups of patients in their IgM reactivity with the tested antigens were found for OspA B. burgdorferi sensu stricto and OspE; for these antigens severe COVID-19 patients demonstrated significantly higher specific IgM levels than the two other groups of patients. Also for OspC B. spielmanii, severe COVID-19 patients demonstrated significantly higher specific IgM levels than the group of participants seronegative to SARS-CoV-2 (Fig. 2, all p-values are listed in Supplementary Table S3, numbers of patients testing positively for each antigen-specific IgM are listed in Supplementary Table S4).

Logistic regression was used as a model for testing the association between number of Borrelia antigens recognized by patients’ IgG (predictor variable) and hospitalization due to COVID-19 infection (response variable). We found that the odds (probability) of hospitalization for COVID-19 increase with each positive test against Lyme disease-related antigen for IgG antibodies (p < 0.05, Fig. 3) but not for IgM (Supplementary Fig. S3). Post-hoc analysis of selected antigens (Osp proteins, p41, and VlsE) was also included; multivariate analysis showed that odds of hospitalization increased with increasing levels of IgG antibodies targeting OspB, OspC B. burgdorferi sensu stricto, and OspC B. spielmanii (logistic regression, p < 0.05) (Supplementary Table S5). For IgM antibodies, the same association was observed for antibodies targeting OspC B. spielmanii and OspE (logistic regression, p < 0.05) (Supplementary Table S6).

In this study we investigated potential correlations between detected antibody levels indicating exposure to Borrelia and the risk of increased severity of COVID-19. Previous exposure to Borrelia was identified by multi-antigenic serological testing, and it revealed that increased levels of Borrelia-specific IgGs strongly correlated with COVID-19 severity and with the risk of hospitalization (Figs. 1 and 3, Supplementary Tables S1 and S2). For Borrelia-specific IgMs, correlations were weaker and mostly insignificant (Fig. 2 and Supplementary Fig. S3, Supplementary Tables S3 and S4).

Typically, pathogen-specific IgM increases at the early stage of infection, while IgG development takes more time. In borreliosis, at the early stage of infection (2–4 weeks) the immunological system detects only a few antigens of Borrelia, e.g. p41 (flagellin) and Osp proteins (outer surface proteins), targeted by IgM antibodies. Borrelia-specific IgGs, in turn, can be observed several weeks after the tick bite, and their increased serum concentration can remain for a long time, even after the resolution of clinical symptoms. OspC, OspA, and p41 are considered the most immunogenic proteins of B. burgdorferi^19,20; consistently, in this study IgGs targeting these antigens were also the most frequent and they reached the highest levels (Fig. 1). Other important targets for IgG diagnostics include VisE, p83, p58, and p17 ^19,20, also detected in this study. Interestingly, in many patients we observed antibodies targeting different species (e.g. B. burgdorferi sensu stricto, and at the same time B. afzelii, and/or B. garinii). This may reflect some cross-reactivity of antibodies, but likely it may result from co-infections with more than one species, which according to the literature may also occur ⁹. Also, severe COVID-19 patients demonstrated significantly higher levels of IgG specific to Anaplasma (Fig. 1), which is often co-transmitted with Borrelia by ticks. This further supports the suggestion that increased risks in COVID-19 are linked to a history of tick bites and related infections (Fig. 4).

Important limitations should be considered for a full understanding of this study’s results. First, diagnostics of Lyme disease (active borreliosis) is still difficult and often unclear. Laboratory testing should be considered in conjunction with potential exposure and compatible clinical symptoms¹⁰; data on patients’ history of tick bites and on potential borreliosis-related symptoms were not available here. Particularly severe COVID-19 patients under intensive care were not able to give them. Thus, in the investigated group at least some individuals may demonstrate immunological memory of previous Borrelia infection/s but not an active disease. On the other hand, difficulties with rapid and unambiguous diagnosis may lead to some Borrelia-infected patients going untreated, with the pathogen affecting their health condition even for a long time.

Second, although this study demonstrated a significant correlation between serum levels of anti-Borrelia antibodies and COVID-19 severity observed in the same individuals, a correlation cannot be assumed to indicate causation. One cannot exclude that there was an unidentified primary factor that in these patients caused both higher vulnerability to Borrelia infection and to severe COVID-19. This could possibly be immunodeficiency or other physiological disorders. Since these patients however demonstrated an efficient antibody response to SARS-CoV-2 (Fig. 1), this issue calls for further research. Alternatively, prolonged Lyme disease might affect the immune system, decreasing its efficacy in antiviral responses in the viral infection. This has never been demonstrated yet, though important effects that Borrelia may have on the immune system have been described^21,22. Of note, demographic parameters have been agreed between groups (Supplementary Fig. S2), so for instance elderly age was not a contributing factor here.

In spite of these important reservations, a strong link between detected anti-Borrelia antibodies and COVID-19 severity was observed in this study (Fig. 1, 2, and 3). This was further supported by post-hoc analysis of IgG targeting selected antigens of Borrelia. These antigens included Osp proteins, p41, and VlsE, being highly immunogenic¹⁹ and important in the life cycle of spirochetes; they are engaged in bacterial colonization of ticks and mammals, virulence, and immune evasion by Borrelia^23–25. The analysis with multivariant logistic regression revealed that increased levels of IgG targeting Osp proteins (only) can be significant predictors of hospitalization due to COVID-19; in this study OspB, OspC B. burgdorferi sensu stricto, and OspC B. spielmanii demonstrated significance in this model (Supplementary Fig. S4, Supplementary Table S5).

To the best of our knowledge, this is the first observation that suggests links between Lyme disease and COVID-19 prognostics. Screening for antibodies targeting Borrelia may contribute to accurately assessing the odds of hospitalization for SARS-CoV-2 infected patients. Though mechanisms of this association are not clear yet, it may help in establishing optimal treatment schedules and in efficient predictions of individual patients’ prognostics, supporting efforts for efficient control of COVID-19.

Participants

Group 1 (hospitalized): Participants with severe COVID-19: infection with SARS-CoV-2 confirmed with PCR diagnostics, hospitalized due to their poor condition (Healthcare Centre in Bolesławiec); these patients required either i) transient, non-invasive assisted respiratory therapy, ii) assisted respiratory therapy with the nasal high-flow cannula, or iii) invasive mechanical ventilation (N = 31);

Group 2 (asymptomatic/mild): Participants with mild or asymptomatic COVID-19, who were treated at home or unaware of being infected, non-vaccinated against COVID-19 but identified as seropositive to anti-SARS-CoV-2 antibodies ²⁶ (N = 28);

Group 3 (control): Participants without diagnosis and history of COVID-19 disease, non-vaccinated against COVID-19 and identified as seronegative to anti-SARS-CoV-2 antibodies ²⁶ (N = 28).

Demographic parameters of the investigated population were different to general demographic parameters of the whole country population, due to the imbalanced representation of hospitalized COVID-19 patients, who tend to be elderly. The studied groups, however, were agreed for concordant demographic parameters without statistically significant differences (Supplementary Fig. S1 and S2).

Blood samples

Serum was collected into tubes (BD SST II Advance), left for 1 h at room temperature (RT) to clot and separated from the clot by centrifugation (15 min, 2000 g, RT), and then stored at − 20°C for further use.

Bioethics statements

The research was approved by the local Bioethical Commission of the Regional Specialist Hospital in Wroclaw (approval no. KB/02/2020, policy no. COR193657) and the procedures were in line with the Declaration of Helsinki. During the interview, all information about the study was provided and written informed consent was obtained from each study participant.

Serological diagnostic tests

Serological identification of SARS-SoV-2 infection was conducted with: Microblot - Array COVID-19 IgG (TestLine Clinical Diagnostics s.r.o.); the array contains selected fragments of specific NCP, RBD and Spike S2 antigens of SARS-CoV-2 virus. Serological identification of Borrelia spp. infection was conducted with: Microblot-Array Borrelia IgG and Microblot-Array Borrelia IgM (TestLine Clinical Diagnostics s.r.o.); the arrays contain specific antigens of Borrelia spp.: VlsE B. afzelii, VlsE B. garinii, VlsE B. burgdorferi sensu stricto, p83, p58, p41 B. afzelii, p41 B. burgdorferi sensu stricto, p39, OspB, OspA B. afzelii, OspA B. garinii, OspA B. burgdorferi sensu stricto, OspC B. afzelii, OspC B. garinii, OspC B. burgdorferi sensu stricto, OspC B. spielmanii, OspE, NapA, and p17. They also include antigens specific for Anaplasma phagocytophilum since this pathogen is often co-transmitted from ticks to a host together with Borrelia spp. (p44, OmpA and Asp62), recombinant antigen TpN17 (IgG) and EBV p18 (IgM) to exclude false-positive reads that might result from cross-reactivity to Treponema pallidum or Epstein-Barr virus. A description of all investigated antigens is presented in Table 1.

Statistical methods

Statistical significance of differences between groups in serum levels of Borrelia spp. antibodies (factor with 3 levels) was tested with one-way ANOVA with the assumption of non-equal SD and Gaussian distribution (Brown-Forsythe and Welch ANOVA test). Dunnett’s T3 multiple comparisons test was used to determine the significance of differences between each pair of groups (GraphPad 9).

Logistic regression analysis was used to assess the risk of severe COVID-19 disease (hospitalization, outcome variable) depending on the presence or levels of antibodies against Borrelia antigens (predictor variable, main effects and intercept only). Spearman's test was used to calculate correlations between levels of antibodies. Statistical analyses were performed using GraphPad Prism 9 (version 9.1.3 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com). Graphs representing boxplots were plotted with the middle line representing the median; upper and lower border of a boxplot are the 75th and 25th percentile respectively. Whiskers represent the maximum and minimum (max/min) read (Tukey method, as plotted by GraphPad 9). Dots represent reads outside of the max/min range (outliers). Statistical tests were two-tailed.

Acknowledgments

This work was supported by the National Centre for Research and Development in Poland, grant no. SZPITALEJEDNOIMIENNE/48/2020. The authors are deeply grateful to all participants who agreed to act as serum donors in this study. Thank you for your help, support, understanding, and for your desire to contribute to scientific solutions to combat the disease.

There are also thanks to Jakub Dąbrowski for help in data processing.

Author Contributions

KD conceived the study. KD, ASzD designed and constructed the study gropus. ASzD, MH, KD, WB, KB, AP, NJ, ZK, KG, TK, AN, KB, MK performed the analyses and contributed to the collection of data. ASzD, KD, MH, WB graphed and interpreted the results. ASzD and KD drafted the manuscript. KD, WW, NJ and UGB critically revised the manuscript. All authors reviewed the manuscript and approved the final version.

Data availability

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Competing Interests

The authors have no relevant financial or non-financial interests to disclose.

Logan, J. G. Lyme disease laid bare. Nature vol. 552 (2017).
Ross Russell, A. L., Dryden, M. S., Pinto, A. A. & Lovett, J. K. Lyme disease: diagnosis and management. Practical Neurology 18, 455–464 (2018).
Flisak, R., Szechiński J & Mrukowicz J. Borelioza z Lyme. in Choroby Wewnętrzne (eds. Szczeklik A & Gajewski P) (Wydawnictwo Medycyna Praktyczna, 2021).
Linden Hu. Diagnosis of Lyme disease. UpToDate https://www.uptodate.com/contents/diagnosis-of-lyme-disease (2021).
van Hout, M. C. The controversies, challenges and complexities of lyme disease: A narrative review. Journal of Pharmacy and Pharmaceutical Sciences vol. 21 (2018).
Stanek, G. & Reiter, M. The expanding Lyme Borrelia complex-clinical significance of genomic species? Clinical Microbiology and Infection vol. 17 (2011).
Rudenko, N., Golovchenko, M., Grubhoffer, L. & Oliver, J. H. Updates on borrelia burgdorferi sensu lato complex with respect to public health. Ticks and Tick-borne Diseases vol. 2 (2011).
Smoleńska Ż, Matujasek A & Zdrojewski Z. Borreliosis – the latest recommendations on diagnosis and treatment. Rheumatology Forum 2, 58–64 (2016).
Tokarska-Rodak, M., Fota-Markowska, H., Kozioł-Montewka, M., Śmiechowicz, F. & Modrzewska, R. The detection of specific antibodies against B. burgdorferi s.s., B. afzelii, B. garinii, and B. spielmani antigens in patients with Lyme disease in eastern Poland. New Medicine 14, 84–87 (2010).
Cutler, S. J. et al. Diagnosing Borreliosis. Vector-Borne and Zoonotic Diseases 17, (2017).
Rozwadowska, B. & Hudzik, G. Borrelia burgdorferi genostrains detected in the Silesian Voivodeship in years 2010–2012. Przegląd epidemiologiczny 66, (2012).
Witecka-Knysz, E. et al. Borelioza: dlaczego diagnostyka jest tak trudna? Diagnosta Laboratoryjny 1, 11–13 (2007).
Sanyaolu, A. et al. Comorbidity and its Impact on Patients with COVID-19. SN Comprehensive Clinical Medicine 2, (2020).
Ng, W. H. et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. mBio 12, (2021).
Thakur, B. et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Scientific Reports 11, (2021).
Sockrider, M. et al. Covid-19 infection versus influenza (flu) and other respiratory illnesses. American Journal of Respiratory and Critical Care Medicine vol. 202 (2020).
Shutikova, A. L., Leonova, G. N., Popov, A. F. & Shchelkanov, M. Yu. Clinical and diagnostic manifestations of tickborne mixed infection in combination with COVID-19. Russian Clinical Laboratory Diagnostics 66, 689–694 (2021).
Piotrowski, M. & Rymaszewska, A. The Impact of a Pandemic COVID-19 on the Incidence of Borreliosis in Poland. Acta Parasitologica (2022) doi:10.1007/s11686-021-00495-0.
Tokarska-Rodak, M. & Kozioł-Montewka, M. The Serology Diagnostic Schemes in Borrelia burgdorferi Sensu Lato Infections – Significance in Clinical Practice. in Lyme Disease (ed. Karami, A.) (InTech, 2012). doi:10.5772/1898.
Aberer, E. Lyme-borreliose - Update. JDDG - Journal of the German Society of Dermatology vol. 5 (2007).
Brouwer, M. A. E., van de Schoor, F. R., Vrijmoeth, H. D., Netea, M. G. & Joosten, L. A. B. A joint effort: The interplay between the innate and the adaptive immune system in Lyme arthritis. Immunological Reviews vol. 294 (2020).
Elsner, R. A., Hastey, C. J., Olsen, K. J. & Baumgarth, N. Suppression of Long-Lived Humoral Immunity Following Borrelia burgdorferi Infection. PLoS Pathogens 11, (2015).
Kenedy, M. R., Lenhart, T. R. & Akins, D. R. The role of Borrelia burgdorferi outer surface proteins. FEMS Immunology and Medical Microbiology 66, (2012).
Bankhead, T. Role of the VlsE lipoprotein in immune avoidance by the lyme disease spirochete borrelia burgdorferi. Forum on Immunopathological Diseases and Therapeutics 7, (2016).
Nakamura, S. Spirochete Flagella and Motility. Biomolecules 10, 550 (2020).
Budziar, W. et al. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021. PLOS ONE 17, e0253638 (2022).

No competing interests reported.

Download PDF

Editorial decision: Major revision
03 Aug, 2022
Reviews received at journal
19 Jul, 2022
Reviewers agreed at journal
14 Jul, 2022
Reviewers agreed at journal
09 Jul, 2022
Reviewers invited by journal
06 Jul, 2022
Editor assigned by journal
06 Jul, 2022
Editor invited by journal
05 Jul, 2022
Submission checks completed at journal
05 Jul, 2022
First submitted to journal
27 Jun, 2022

You are reading this latest preprint version

Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp.

Status:

Version 1

Abstract

Figures

Introduction

Results

Discussion

Methods

Participants

Blood samples

Bioethics statements

Serological diagnostic tests

Statistical methods

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1